Agoracom Blog Home

Archive for the ‘Marijuana Company of America’ Category

« Older Entries
Newer Entries »

Marijuana Company $MCOA of America Engages Eddy Pham & Company to Launch Comprehensive Hempsmart(TM) CBD Retail Marketing Campaign $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 10:23 AM on Tuesday, March 27th, 2018

15233 mcoa

  • Engaged Eddy Pham & Company (EPCO) to provide retail marketing and advertising services for its hempSMART™ branded products
  • CEO Donald Steinberg, stated, “MCOA is honored to have EPCO on as a marketing partner for our hempSMART product line. The impressive marketing strategy that EPCO will be implementing with our products will help secure hempSMART as one of the leading hemp-based cannabinoid companies in North America.”

Escondido, California–(March 27, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis company, is pleased to announce that it has engaged Eddy Pham & Company (EPCO) to provide retail marketing and advertising services for its hempSMART™ branded products.

Eddy Pham & Company is a direct to consumer full-service marketing company that will provide MCOA‘s hempSMART product line with a fully integrated, multi-channel transactional marketing campaign focused on digital advertising, infographics, content marketing, customer incentives and acquisition, a broad social media presence as well as search engine marketing and optimization that includes comprehensive research and analytics. EPCO will also be providing outsourced customer service and fulfillment services for hempSMART orders made through their campaign.

Since 1993, EPCO’s CEO, Mr. Eddy Pham has had a long and successful career managing transactional marketing campaigns. Mr. Pham has been involved in the product development, manufacturing, distribution, and campaign marketing of a number of the well-known product lines on the market. With the experience gathered from managing the manufacturing for over 160 products, EPCO is poised to help the hempSMART family of products be successful from building brand equity to overall increased sales. EPCO will utilize its partnerships within the transactional industries to help bring hempSMART to consumers who are looking for all natural, hemp-derived, full spectrum CBD and other future cannabinoid (CBC, CBG, CBN) based proprietary formulated products that are in development.

CEO Donald Steinberg, stated, “MCOA is honored to have EPCO on as a marketing partner for our hempSMART product line. The impressive marketing strategy that EPCO will be implementing with our products will help secure hempSMART as one of the leading hemp-based cannabinoid companies in North America.”

Eddy Pham states, “In over two decades of product development and transactional marketing, I can say that hempSMART produces quality products that truly work. I personally have not been this excited in a long time to work on a product line that can truly bring relief to its users.”

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

About Eddy Pham & Company
Eddy Pham & Company is a direct to consumer full service company that focuses on transactional marketing, product development, distribution, and operational campaign management. EPCO has branded and launched over 160 recognized and successful brands over the last 25 years. The company offers a collection of end to end services spanning various media verticals focusing on revenue enhancement.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , ,
Posted in All Recent Posts, Marijuana Company of America | Comments Off on Marijuana Company $MCOA of America Engages Eddy Pham & Company to Launch Comprehensive Hempsmart(TM) CBD Retail Marketing Campaign $AERO $CBDS $CGRW $APH.ca $GBLX

#Marijuana stocks just got less risky, GMP Securities says $N.ca $NXTTF.ca $TBP.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:41 PM on Monday, March 26th, 2018

  • Recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities
  • Canada is poised to be an global leader in the cannabis space
  • This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana
  • bill passed 44 to 29

March 25, 2018 By Jayson MacLean

Canada’s still-developing cannabis sector has seen its share of fortunes won and lost over the past year, with stock prices skyrocketing in a matter of weeks over December and January, only to pull back considerably in the time since.

But recent developments on the political and regulatory end are likely to add stability to the emerging market, says Martin Landry, analyst with GMP Securities, who says Canada is poised to be an global leader in the cannabis space.

This past Thursday saw Canada’s Senate voting on its second reading of Bill C-45, the so-called Cannabis Act which would legalize the recreational use of marijuana. Although the vote was predicted to be tight, as some senators in favour of the legislation were out of Ottawa on committee work and Conservative senators promising to vote en masse against, the bill nevertheless passed 44 to 29.

That bodes well for the bill, says Landry, who projects a late summer/early fall opening up of the rec cannabis market.

“[The Senate vote] provides a positive read-through in our view for the potential outcome of the final third reading vote, as the majority of the Independent Senators Group appear to be aligned with the Liberals,” Landry said in a note to clients on Friday. “In a 3rd reading scenario where all Liberals and Conservatives vote for and against Bill C-45 respectively, this would suggest ~73 per cent of independents (versus 95 per cent at second reading) would need to vote in favour for Bill C-45 to become law.”

As well, this past week Health Canada released its fourth quarter 2017 data on medical marijuana use, finding that patient registrations were up 14 per cent on the quarter to 269,502, while total volume of medical cannabis grew around 10 percent on the quarter and around 34 per cent year-over-year, the best growth rate over the past three quarters, says Landry.

Also coming from Health Canada were summary results from public consultations on the new cannabis regulations, held during a 60-day period starting this past November. The consultations drew in approximately 4,000 responses, covering all aspects of the proposed regulations including licensing and permits, security clearance and cannabis tracking, product packaging and labelling and the medical use of cannabis.

Some notable results include strong support from respondents for a quick roll-out on regulations regarding cannabis edibles along with majority support for the government’s plans concerning licensing and product labelling and plain packaging.

Landry says that going forward the report should feed into guidance and regulations for industry participants. On the issue of product labelling, the analyst says that Health Canada’s push for plain packaging could make it “difficult for licensed producers to differentiate their brands on the basis of packaging, however advertising rules are not expected to be more restrictive than those for tobacco,” Landry says.

In all, Landry sees the ramped up medical market and the maturing regulatory landscape to be a win for Canadian companies, who now have a head start over the competition when it comes to the industrial production of cannabis within a tightly regulated environment.

Landry says that having LPs required to deliver secure and stable production has “led Canadian licensed producers to build pharmaceutical grade production facilities, develop solid cultivation know-how and create a large bank of genetics,” he says. “Combined with well capitalized balance sheets, we believe that Canadian LPs are well positioned to become global leaders in the cannabis sector.”

Source: https://www.cantechletter.com/2018/03/marijuana-stocks-just-got-less-risky-gmp-securities-says/

Tags: , , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on #Marijuana stocks just got less risky, GMP Securities says $N.ca $NXTTF.ca $TBP.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:04 AM on Monday, March 12th, 2018

15233 mcoa

  • Announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week,
  • One of the largest business-to-business trade shows in the world.

Escondido, California–(March 12, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week, one of the largest business-to-business trade shows in the world.

Convenient Hemp Mart has developed a collection of Benihemp branded, sample sized products for consumers including topicals, tinctures, and edibles packaged in 1-day, 2-day, and 30-day supplies. The target markets are convenience stores, smoke shops, gas stations and similar types of retail businesses where CBD commerce has a greater likelihood of generating sales from the impulse buyer at the register.

Convenient Hemp Mart is officially launching the Benihemp product line at ASD Market Week (www.asdonline.com) in Las Vegas, NV. ASD is a comprehensive business-to-business trade show for retail merchandise that annually hosts 45,000 buyers from over 90 countries, representing major department stores, convenience stores, gift shops, grocery stores, and other retail stores. Out of the 45,000 attending the show, 98% of the attendees have purchasing power, and the average buyer spends a total of $82,500 on product orders per show. Benihemp will be located in the lower south hall at booth SL2449.

MCOA has invested $100,000 into Benihemp in exchange for a 25% equity stake in Convenient Hemp Mart, LLC.

Donald Steinberg CEO of MCOA stated “Marijuana Company of America is excited for the opportunity to diversify product distribution into retail markets across the country. We believe in the Convenient Hemp Mart team and their ability to successfully launch Benihemp at ASD.”

“We are eagerly looking forward to the unveiling of the Benihemp brand at this ASD Marketplace event. With the ever-growing Convenience store marketplace hitting a new record of over 140 billion dollars in annual sales last year, we believe this is the perfect place to present the first industrial Hemp derived products developed specifically for this market. Our team has worked very diligently for the launch of the Benihemp brand and are all thrilled that it has finally come to life,” said Sam Girges of Benihemp.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our Benihemp Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , , ,
Posted in Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

How to Invest in Canada’s Coming Legal #Cannabis Boom $N.ca $TBP.ca $MCOA

Posted by AGORACOM-JC at 4:23 PM on Tuesday, February 13th, 2018
  • In just the first six weeks of 2018, 15 of Canada’s 28 public cannabis companies have raised a combined C$1.2 billion selling securities.
  • Many investors have opted instead to focus on Canada, which has a federally legal medical cannabis program and is on the cusp of becoming the first country with federally legal access for all adults

Investing in US-based cannabis companies can be tricky, but Canadian-based companies have few of the same legal risks. (MJ_Prototype/iStock)

For those looking to invest in the legal cannabis industry, companies in the U.S. offer a quandary. Since cannabis remains federally illegal, these companies are all at risk of prosecution, a risk that may have increased earlier this year when Jeff Sessions rescinded the Cole Memo, the departmental guidance that protected states and operators as long as they adhered to the memo’s eight principles.

In just the first six weeks of 2018, 15 of Canada’s 28 public cannabis companies have raised a combined C$1.2 billion selling securities.

Many investors have opted instead to focus on Canada, which has a federally legal medical cannabis program and is on the cusp of becoming the first country with federally legal access for all adults.

What makes the Canadian cannabis sector even more interesting than its ability to service its own population legally is that many of the licensed producers (LPs) are actively involved in international markets like Europe, Australia, Latin America and Israel.

These companies are not only able to export but are also in the process of applying for licenses to operate cultivation facilities in conjunction with local investors. Germany is a particularly exciting medical cannabis market due to insurance reimbursement and distribution through traditional pharmacies.

Your Options: 28 Public Companies

Health Canada, which oversees the licensing and regulation of the Canadian cannabis industry, has approved 89 licenses, some of which have been awarded to companies holding multiple licenses. There are 28 cannabis companies that trade publicly on the Toronto Stock Exchange, the TSX Venture Exchange or the Canadian Securities Exchange. Many of these have U.S. listings as well on the OTC.

So far in just the first six weeks of 2018, 15 of these public companies have raised a combined C$1.17 billion selling securities. This access to capital is a big difference between Canadian and U.S. cannabis companies. I expect that there will be another five or so trading publicly within the next three months.

I’ve created an index for those interested in tracking the performance of this sector: the Canadian Cannabis LP Index. I break it into three different segments, including Tier 1, the largest producers, Tier 2, those that are generating sales but not at the same scale as the leaders, and Tier 3, those companies that have received their license to cultivate but aren’t yet permitted to sell. Overall, the sector has performed very well over the past two years, though it has undergone a sharp correction over the past few weeks.

The top tier includes six companies that are all generating annual sales in excess of C$16 million. These include Aurora Cannabis, Aphria, CanniMed Therapeutics, MedReleaf, CannTrust Holdings and Canopy Growth. CanniMed and Aurora Cannabis are in the process of merging, with an expected closing next month. Note that Aurora Cannabis and Canopy Growth are clients of New Cannabis Ventures, where I serve as managing partner. This article is not intended to be a recommendation of these companies or any others that I mention.

Daily Trading Exceeds C$1 Billion

With the exception of CannTrust, which trades on the Canadian Securities Exchange, each of the others trades on the Toronto Stock Exchange. The combined daily trading value of Aphria, Aurora Cannabis and Canopy Growth has been exceeding C$1 billion regularly, meaning that investors can buy and sell these names without moving the market. The other 22 publicly-traded companies also provide reasonable liquidity for the most part.

At least two exchange-traded funds (ETFs) are heavily invested in Canadian LPs.

U.S. investors interested in buying Canadian licensed producers are best off opening an account that allows them to buy and sell Canadian securities directly, but it is also possible to buy the U.S. listings.

Another alternative is to consider exchange-traded funds (ETFs). I wasn’t a fan of Horizons Marijuana Life Sciences Index ETF when it debuted in April, but it has improved. At this point, Canadian LPs make up more than 80% of the Horizon ETF’s holdings. The fund manager is launching a second ETF this week, the Emerging Marijuana Growers Index ETF, which includes smaller companies, over half of which are Canadian LPs.

High Valuations, Higher Expectations

Despite the recent decline in prices, the valuations of Canadian LPs are high relative to their current rate of sales. Still, with legalization kicking in later this year, future sales are expected to rise substantially. Canopy Growth and Aurora Cannabis have market capitalizations of about C$6 billion, followed by Aphria at C$2.8 billion, MedReleaf at C$1.9 billion, CanniMed at C$882 million and CannTrust at C$793 million. The U.S market caps are about 20% lower based on the current Canadian dollar exchange rate of $0.795.

Bottom line: Canadian cannabis companies are perhaps safer investments than those in the U.S. due to being federally legal, but they have performed very well and may be overvalued despite a recent sell-off. Investors looking to capitalize on global cannabis opportunities should consider exploring this group of companies, which currently numbers 28 and is likely to expand in the near term.

Next up: I discuss the hazards of investing in the stocks of publicly-traded producers of CBD from industrial hemp.

As an owner of New Cannabis Ventures, Alan Brochstein works with several publicly-traded and privately held cannabis companies as he discloses here. In the event he mentions a company that is a client, he will disclose it in the article as well.Source: https://www.leafly.com/news/industry/how-to-invest-in-canadas-coming-legal-cannabis-boom

Tags: , , , ,
Posted in Marijuana Company of America, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on How to Invest in Canada’s Coming Legal #Cannabis Boom $N.ca $TBP.ca $MCOA

BMO $BMO.ca marks first foray by a major Canadian bank in #marijuana sector with $175M deal $TBP.ca $N.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:42 PM on Thursday, January 18th, 2018

  • Bank of Montreal broke new ground Wednesday for the “Big Five” Canadian lenders with its participation in a major marijuana deal
  • Canopy Growth Corp., Canada’s largest licensed producer of medical cannabis, announced an approximately $175-million bought-deal offering Wednesday

Smiths Falls, Ont.-based Canopy Growth Corp., Canada’s largest licensed producer of medical cannabis, announced an approximately $175-million bought-deal offering Wednesday of a little more than five million shares of the company.

Canopy noted in a release that GMP Securities LP and Bank of Montreal-owned BMO Capital Markets were leading the transaction for the company as joint bookrunners, marking the first time a major Canadian bank has helped head an equity financing for a publicly traded company in the medical marijuana industry.

“This is the first time a major Canadian bank-owned brokerage has participated in a cannabis securities issue,” wrote Chris Damas, editor of the BCMI Cannabis Report.

A spokesperson for Canopy confirmed that the transaction marked the first such foray by a Big Five Canadian bank.

“Although this does not guarantee participation in the cannabis sector by all six of the largest Canadian Schedule 1 banks (BMO had already been a banker for cannabis companies), it is very positive for the sector, all things being equal,” Damas added.

Other major Canadian banks have yet to dive into the country’s growing cannabis sector in the same way BMO has, and are likely hesitant to do so given their significant business in the United States, where marijuana is still illegal under federal law. But some banks, including BMO, have provided business accounts for cannabis companies, according to Bloomberg.

That stance may now be starting to soften amid a fundraising spree in the Canadian marijuana industry, which had been taking place without the country’s biggest banks. Companies involved in the already legal medical pot business have been seeking funding to serve the coming recreational market set to be legalized by the federal government this summer.

Royal Bank of Canada told the Financial Post in a statement last week that it “currently does not provide banking services to companies engaged in the production and distribution of marijuana.”

“We recognize that the legislative landscape is evolving and we are undergoing a review of our policies,” added the lender.

A spokesperson for Bank of Nova Scotia told the Post on Friday that “we must balance that with our commitment to effectively manage all business risks.”

“While we understand there is a robust debate in Canada and abroad, our priority is to manage risk for our customers and stakeholders to ensure they are protected,” said Scotiabank’s Rick Roth in an email. “Should there be significant change to industry legislation or regulation, we will revisit our risk assessment and make risk policy adjustments if warranted.”

Toronto-Dominion Bank and the Canadian Imperial Bank of Commerce either declined to comment or had yet to respond as of Thursday morning.

Canopy said its agreement with the underwriters includes an over-allotment option for them, allowing for the purchase of up to 759,000 additional shares at the offering price of $34.60 per share, worth nearly $26.3 million. The company said that the deal is expected to close on Feb. 7, subject to some conditions, and that the net proceeds will be used “for capital expenditures for capacity expansion, working capital, and general corporate requirements.”

Source: http://business.financialpost.com/investing/bank-of-montreal-marks-first-for-major-canadian-lenders-with-175m-marijuana-deal

Tags: , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on BMO $BMO.ca marks first foray by a major Canadian bank in #marijuana sector with $175M deal $TBP.ca $N.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America Launches New CBD Product hempSMART™ Pet Drops $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:37 AM on Thursday, January 11th, 2018

15233 mcoa

  • Release of hempSMART™ Full Spectrum Pet Drops formulated for cats and dogs.
  • Formulated with 250mg of full spectrum non-psychoactive Cannabidiol (CBD) derived from industrial hemp

 

ESCONDIDO, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) — via NetworkWire – MARIJUANA COMPANY OF AMERICA INC. (“MCOA” or the “Company”) (OTC:MCOA), an innovative hemp and cannabis corporation, is pleased to announce the release of hempSMART™ Full Spectrum Pet Drops formulated for cats and dogs.

Each bottle of hempSMART Full Spectrum Pet Drops is formulated with 250mg of full spectrum non-psychoactive Cannabidiol (CBD) derived from industrial hemp. The new specially formulated product contains naturally occurring CBD derived from hemp seed oil, full spectrum hemp extract, fractionated coconut oil, and a rich bacon flavor.

Donald Steinberg, MCOA’s CEO said, “Our new hempSMART product is a natural option for pet owners who care about supporting their animals’ healthy energy levels as well as optimizing their health. Our hempSMART product line will continue to expand to other popular areas of consumer interest to give our affiliates what they need to succeed.”

In reviewing pet supplement trends for 2017, Watson, Inc.’s Mona Hollums observed that natural pet supplement sales nearly doubled between 2008 and 2014. With the increasing focus on pet health, the market for pet supplements is projected to show significant and continuing expansion. Projections show that U.S. retail sales of pet supplements and nutraceuticals treats will grow 3%-5% annually, bringing the market to $1.6 billion. Globally, the pet supplement market is also expected to grow even further. Between 2016-2020, sales are projected to increase over 5% and will continue to yield lucrative investment payouts.

About Our hempSMART Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™â€, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact: 
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , , ,
Posted in Featured, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America Launches New CBD Product hempSMART™ Pet Drops $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America $MCOA and Global #Hemp Group $GHG.ca Issue Final Report on New Brunswick Hemp / #CBD Project $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:38 AM on Wednesday, January 10th, 2018

15233 mcoa

  • Provides a final report on the first phase of their industrial hemp project in New Brunswick
  • In this first phase of MCOA’s and GHG’s multi-phase hemp project, the Partners successfully cultivated industrial hemp during the 2017 growing season
  • Objective of phase one was to re-introduce hemp into the area, to ensure that it could be productive under New Brunswick growing conditions, prior to significantly increasing cultivation acreage, and building a hemp processing facility in the region

Escondido, California–(January 10, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, and Global Hemp Group, Inc. (“GHG”) (CSE: GHG) (FSE: GHG) (OTC Pink: GBHPF) are pleased to provide a final report on the first phase of their industrial hemp project in New Brunswick.

On September 5, 2017, MCOA and GHG announced their joint venture to develop commercial hemp production on the Acadian peninsula of New Brunswick, Canada.

In this first phase of MCOA’s and GHG’s (the “Partners”) multi-phase hemp project, the Partners successfully cultivated industrial hemp during the 2017 growing season (see Phase One Hemp Trial Results below). For this phase of the project, the Partners only grew hemp for research purposes, as this was the first time in 20 years that industrial hemp was grown in the region. The objective of phase one was to re-introduce hemp into the area, to ensure that it could be productive under New Brunswick growing conditions, prior to significantly increasing cultivation acreage, and building a hemp processing facility in the region.

The Partners are preparing for proposed changes to Canadian legislation expected in 2018, that will permit cannabidiol (CBD) extraction from industrial hemp. Health Canada is currently consulting industry representatives regarding regulations that will accompany the new cannabis legislation expected by July 1, 2018.

The Partners are now focusing on the next season of crops. Farmers have been recruited and a minimum of 125 acres of hemp cultivation is planned for 2018, with the goal of increasing the acreage under cultivation to 1,000 acres by year three of the project. This first commercial crop will focus on CBD extraction. The Partners are currently considering sites in northeast New Brunswick to locate their processing facilities. In addition, discussions are underway regarding the purchase of extraction equipment for cannabinoids, and straw processing equipment for building materials. The companies expect the facilities to be in place and operational for the 2018 harvest in October.

Under the joint venture MCOA will facilitate access to international markets for the project’s CBD production, product development and distribution, while GHG will provide technical and management expertise. MCOA has Right of First Refusal as the primary off-taker of the cannabinoids from all future hemp cultivation projects.

RENEWAL OF GHG’S HEMP LICENSE IN CANADA

GHG’s industrial hemp license was renewed for 2018. Under current legislation, hemp flowers and leaves grown under field conditions cannot be processed. It is expected that this will be allowed under new 2018 regulations, but will still require additional licenses: one to extract the CBD and another to sell CBD for medical or non-medical purposes. In anticipation of this change, GHG will be applying for a license under the Narcotics Control Regulations (NCR) to extract CBD, and an additional license under the Access to Cannabis for Medical Purposes (ACMPR) to sell it to wholesale and retail customers in Canada.

FINAL TRIAL RESULTS

The trial consisted of fifteen test plots with three different varieties and as many planting densities of hemp, in two different locations east and west of Bathurst.

The trials were sampled, and collected materials were measured at Collège Communautaire du Nouveau Brunswick (CCNB), Grand Falls laboratory, where standard drying and measuring procedures were applied to the hemp straw, flowers, and leaves. Straw yields averaged 1.0-2.5 T/ha, whereas the combined flowers and leaves of the plant averaged 1.25-2.10 T/ha. The Partners are confident that with an earlier planting date, adequate soil preparation, and a higher fertilizer application, yields will be improved in future seasons.

Cannabinoid analysis of the flowers and leaves was completed by RPC – Science & Engineering (RPC), an accredited laboratory located in Fredericton, NB. Contrary to expectations leaves, rather than the flowers, contained a greater concentration of CBD, largely explained by laboratory procedures. The highest concentration that was found was the CFX-1 leaf sample that resulted in 1.46% for the 30 kg/ha plant density compared to 1.17% for the flowers. Also, it should be noted that the CBD concentration in flowers is consistently higher at densities of 30 kg/ha across all varieties that were tested.

Frank Giese, an advisor to GHG, will consult on the 2018 cultivation to assist in increasing both plant yield and cannabinoid production. Through his experience, he has bridged the fundamentals of scientific research and hemp/cannabis breeding, as well as the use and development of modern cultivation and processing techniques in his breeding work. He has become proficient in breeding cannabinoid rich varieties of hemp, as well as being very experienced in auto flower breeding.

Donald Steinberg, CEO of MCOA, stated, “We are excited to complete the first phase of industrial hemp trials in Canada, and we look forward to continue expanding operations in Canada. Our joint venture with GHG allows MCOA the opportunity to expand the Company’s operations on an international level. Both Companies are excited about the endless possibilities for hemp derived CBD product this year in Canada.”

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Global Hemp Group Inc.

Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp and cannabis, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and value, and establish a greater collective valuation.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Marijuana Company of America, Inc.
Investor Relations
1+(888)-777-4362
[email protected]

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America | Comments Off on Marijuana Company of America $MCOA and Global #Hemp Group $GHG.ca Issue Final Report on New Brunswick Hemp / #CBD Project $AERO $CBDS $CGRW $APH.ca $GBLX

Canadian #cannabis producers set their sights on global domination $N.ca $TBP.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 11:10 AM on Friday, January 5th, 2018

  • Medical research forcing an end to prohibition
  • “I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.
  • In recent months, more than a dozen countries have legalized medical marijuana

Medical marijuana consumers in Prague rang in 2018 with a new Canadian import, Tilray Milled Cannabis, a high THC marijuana product grown on Vancouver Island.

The Czech Republic is just the latest nation to sell Canadian weed, joining Germany, Australia, New Zealand and a growing list of other nations which are turning to Canada as a safe and legal source for medical grade cannabis.

In recent months, more than a dozen countries have legalized medical marijuana. New laws are pending in at least a dozen more as national regulators and even the World Health Organization recognize legitimate medical uses for a drug which had long been banned under international treaties.

The moves have sparked an unprecedented demand for legally grown, high quality marijuana, as well as the oil which is extracted from it. Seven Canadian producers have been granted licences to export the crop. By the end of March they will have sent 528 kilograms of dried cannabis flower and 911 litres of oil overseas. That may well be just an initial trickle, as the floodgates open on an international medical cannabis market.

“I’ve never experienced anything like this,” says Ranjeev Dhillon, a corporate lawyer and partner at the law firm Bennett Jones. Most of his practice now centres on the cannabis export business.

Brendan Kennedy of Tilray says Canada is the source of the safest product when regulators in other countries go looking for medical marijuana. (Evan Mitsui/CBC)

“I think it means that we’ll be a global player,” he says, stressing this is a positive development for the Canadian economy. “This could be our opportunity to be viewed the same as we are in mining or hockey. We’ll be world class and be world leaders and I think that will stay to be the case for a very, very long time.”

Medical research forcing an end to prohibition

For decades an international ban on the production and use of cannabis kept to a minimum any legitimate research into potential medical uses. Prohibition ensured that marijuana cultivation stayed in the hands of illegal growers, and distribution was limited to the criminal underground.

But many users saw value in cannabis as treatment for a variety of conditions, ranging from controlling epileptic seizures to pain relief to stress control.

Israeli scientist Raphael Mechoulam began limited research on the drug in the early 1960s, which led to the discovery of the human endocannabinoid system. By the mid-1990s, scientists determined that cannabinoid receptors play a vital role in the function of the human body. For the first time synthetic cannabinoid derivatives were approved for medical use, primarily for the treatment of nausea and wasting syndrome.

At the same time anecdotal evidence was building to suggest cannabis could have other, more widespread medical uses. Patients who claimed benefits from cannabis went to court seeking the right to use marijuana as medicine without facing the risk of criminal prosecution.

In 2000 the Ontario Court of Appeal ruled that Terry Parker, a man with severe epilepsy, should have the right to use marijuana to moderate his severe seizures.

One year later, Canada’s Medical Marijuana Access Program was introduced, allowing patients who had obtained a doctor’s consent to grow their own marijuana under a special permit. By 2013 more than 28,000 Canadians had been granted personal use production licences, leading to a flood of unregulated home-grow operations, and along with it a risk of fires, mould contamination in homes, and legally grown weed being diverted to the black market.

In an effort to crack down on the home grow-ops, the Harper Conservative government introduced new legislation that established legal grow operations which could provide medical marijuana through a mail order service. The Marijuana for Medical Purposes regulations, enacted in 2014, set Canada apart as the first nation to establish a regulated commercial cannabis cultivation industry.

Canadian pot finds a role in the world market

As Canada moves towards legal recreational weed in July, the number of licensed growers has swelled to 84, production is skyrocketing, and research into new growing techniques and improved strains is increasing exponentially. This has placed Canada in a unique role as other nations scramble to find safe and legal supplies of medical cannabis.

Cam Battley, executive vice president of Aurora, shows off Aurora Vie’s Pointe-Claire, Que., facility. Canadian producers have expertise in greenhouse technology, extraction methods, strains and genetics. (CBC)

“When regulators in other countries are looking for a product, Canada is really the source of the safest product. It’s the safest bet,” explains Brendan Kennedy, the CEO of Nanaimo-based Tilray, a pioneer in cannabis exports.

Tilray is among several Canadian producers already exporting to Germany, which established a widespread marijuana access program last spring. Not only is cannabis stocked in German pharmacies, the government pays for the drug under its government health insurance program.

Until it can establish a domestic industry, Germany is importing from Canada. Along with Tilray, Canadian producers Aurora, Cronos and Canopy Growth are tapping the German market. Aurora has even gone a step further, purchasing pharmaceutical supplier Pedanios, with an eye to expanding its distribution in the European market.

Following Germany, several other European countries, including Greece, Italy, Poland and the Czech Republic, passed new medical cannabis laws. Several others are following. A report published in November places the value of the European cannabis market at $84 billion Cdn a year.

That’s led Tilray to begin construction of a $30-million production facility in Portugal to help supply the growing market.

Beyond exports, Canada has expertise

“Part of the reason we decided to invest in a cultivation facility in Portugal was that we also saw a massive increase in demand for medical cannabis product in the EU,” explains Kennedy, who sees a bright future well beyond Canadian exports.

Canadian expertise in growing and greenhouse technology, extraction methods, strains and genetics, along with plain old business know-how, are also in demand. In addition to exports, Canada’s cannabis companies are also teaming up with local partners to build facilities in Germany, Denmark and Israel.

Australia is seen as another prize for Canadian producers. When it announced last February that it would allow importation, Canadian producers Aurora, CannTrust, Canopy, MedReleaf and Tilray swooped in, not only with bags of weed and vials of oil, but with partnerships to build facilities there.

Peru and Mexico have also passed legislation to legalize medical cannabis, and Canadian companies are promising further announcements soon. Overall, they say, the world market could be worth around $200 billion.

What it all means

The rapid legalization of medical cannabis has spurred new research into potential treatments using the drug. In Israel, where the medical research began, there are about 120 trials underway using components of the marijuana plant.

Neil Closner, CEO of Ontario-based MedReleaf, believes Canadian medical marijuana producers have the potential to become global giants. (Canadian Press)

As cures and treatments are discovered and proven, the role of cannabis is sure to expand, creating even greater potential beyond flowers and oil. CEO of Markham-based MedReleaf Neil Closner believes at least two or three of Canada’s producers will become global giants.

“I think overall who wins is Canada. I think we’ve got a leg up on the rest of the world, which is very exciting at a national level for us. I’d like to think that MedReleaf is strongly positioned to be one of the few handfuls of global winners.”

And while California is the latest U.S. state to legalize marijuana, American producers are shut out of the global market because of the federal prohibition on the drug.

That leaves Canada room to pursue the international market and all the potential riches that go with it.

Source: http://www.cbc.ca/news/business/medical-marijuana-canadian-export-1.4470407

Tags: , , , ,
Posted in All Recent Posts, Featured, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on Canadian #cannabis producers set their sights on global domination $N.ca $TBP.ca $MCOA $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America’s $MCOA Overview of 2017 Highlights $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:47 AM on Wednesday, January 3rd, 2018

15233 mcoa

2017 HIGHLIGHTS

  • MCOA became a fully reporting company by filing a Form 10 with the SEC in May of 2017
  • In Q1 2017, MCOA entered into a joint venture partnership with Bougainville Ventures, Inc
  • In Q3 2017, MCOA and Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) entered into a joint venture partnership to develop commercial hemp production and processing in New Brunswick
  • In October 2017, MCOA and GHG jointly entered into a letter of intent  with Space Cowboys, Inc.

Escondido, California–(January 3, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce its 2017 year-end review to its valued shareholders and interested parties.

Donald Steinberg, CEO of MCOA, said: “I am the founder of multiple startups, including Medical Marijuana Inc. (OTC: MJNA), which has a market cap of over 300 million dollars. I am aware of the challenges and opportunities these endeavors present, and the need for a strong foundation to build upon. Having experience in the structuring, development and operations of large global marketing companies in various industries, I believe Marijuana Company of America and its subsidiary hempSMART are poised to deliver significant value to our shareholders based on the foundations and accomplishments made in the past year. 

The Company has fulfilled its promise to its shareholders by becoming an audited and fully transparent reporting company with the Securities and Exchange Commission. We are participating in the cannabis space with our leasing operation in Washington. The hempSMART team has developed a line of products that can be viewed at www.hempsmart.com. We completed joint hemp trials in New Brunswick, Canada with Global Hemp Group, Inc. in 2017, and we expect to be starting commercial production in Spring 2018. There are a number of other projects we are completing due diligence on. I am thankful to the teams at MCOA and hempSMART for their accomplishments and due diligence in working through these various projects.  We will continue to build upon the diligent work of the past year as we continue to move forward and execute our business plan.”

Updates on hempSMART Products

The Company’s wholly owned subsidiary, hempSMART, Inc., distributes industrial hemp based CBD wellness products via network marketing. In September 2017, the Company completely revamped its website and network marketing platform to provide customers and affiliates with the necessary tools needed to become successful in the expanding $1.9 Trillion Wellness Industry. The Company has successfully filed a patent application with the U.S Patent and Trademark Office for full patent protection on its proprietary CBD formulation: “hempSMART™ Brain.” Also in 2017, hempSMART released two new products: “hempSMART™ Full Spectrum Drops” (Orange, Mint, Lemon, and Strawberry) and “hempSMART™ Pain Capsules.” Several more products are in development and the Company anticipates their release in Q1 2018.

Filing Form 10 with SEC and Completing Audit

MCOA became a fully reporting company by filing a Form 10 with the SEC in May of 2017. A PCOAB registered audit firm (L & L CPAs PA) completed a two-year audit of the Company’s 2015 and 2016 financial statements. This is an integral step to qualifying the Company to uplist its trading tier with OTC Markets to the OTCQB. This is an important step in helping MCOA raise necessary capital to fund it projects and expand operations, as well as provide more transparent and reliable information to investors. Currently, the Company is in the process of preparing and filing an S-1 registration statement with the SEC in order to raise the necessary capital to fund its aggressive growth goals for 2018. Due to the inherent legal complexity of the cannabis industry, it took considerable effort to address SEC comments pertaining to disclosures of our business and corresponding products. We believe there is a great deal of shareholder value by the Company distinguishing itself from a majority of cannabis public companies that elect not to be fully reporting SEC filers.

Cultivation Joint Venture in Washington State

In Q1 2017, MCOA entered into a joint venture partnership with Bougainville Ventures, Inc. (“BV”), who plans to construct a 30,000 sq. ft. greenhouse cultivation facility in Oroville, WA. The facility will accommodate a Tier-3 production and processing I-502 tenant with years of experience in cannabis cultivation. In Q4 of 2017, MCOA completed financing of $800,000 in cash and 15 million shares of the Company’s common stock to complete the amended terms of the agreement. The delivery of the first pre-designed greenhouses, with full tracking and reporting protocols has arrived and completed construction of the six greenhouses, totaling in a one-acre footprint, is expected in Q1 2018. This joint venture project is solely for the purpose of cultivation and processing of legal marijuana within the state of Washington only and not beyond its borders. The Company will lease the turnkey property to the licensed tenant, thus acting solely as a landlord. As of December 31, 2017, the first greenhouse was purchased and in the process of being constructed.

JV with Global Hemp Group in Canada

In Q3 2017, MCOA and Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) entered into a joint venture partnership to develop commercial hemp production and processing in New Brunswick, Canada. MCOA and GHG have now completed the first phase of hemp trials, receiving research support from the Collége Communautaire du Nouveau Brunswick (CCNB). MCOA is granted a Right of First Refusal as the primary recipient of any raw materials produced from the project, which we expect will harvest its first commercial crop of 125 acres in Q4 2018.

MoneyTrac Technologies Investment

In July 2017, MCOA completed an investment of $250,000 into MoneyTrac Technology, Inc. (“MTT”), a subsidiary of Global Payout, Inc. (OTC: GOHE) in exchange for 15% equity position in the company, to help establish and market MTT as an alternative banking solution for the Cannabis industry. MTT currently has the ability to integrate and streamline electronic payment processing such as E-wallet, mobile applications, debit cards, and credit cards. Currently, MoneyTrac Technology has strategic partnerships with top cannabis services such as GreenRush, BlazeNow, High Grade Management Group, and PotSaver, which was a majority acquisition last October.

BeniHemp Investment

At the end of Q4, the Company announced an investment of $100,000 for a 25% equity stake in Convenient Hemp Mart, LLC’s “BeniHemp” branded products to target convenience stores for CBD product distribution. BeniHemp products will include topicals, tinctures, and edibles conveniently packaged in 1-day, 2-day, and 30-day supplies. The target market is convenience stores, smoke shops, gas stations and similar small retail businesses. The expectation is that there will be a full launch and website online in January 2018.

Space Cowboys, Inc.

In October 2017, MCOA and GHG (“the Companies”) jointly entered into a letter of intent (LOI) with Space Cowboys, Inc. (“Space Cowboys“). Pursuant to the terms of the LOI, the Companies intended to invest US$2.5 Million in exchange for a 25% equity interest in Space Cowboys. However, the Companies are unable to complete due diligence and will not be moving forward with this project.

Joint Venture in Adelanto, CA

In March, MCOA entered into a joint venture agreement with GateC Research Inc. (“GCR”) for the purpose of developing a turnkey cultivation facility in Adelanto, California for leasing to GCR which owns a local permit for cultivation. GCR and MCOA are in the process of identifying and securing property to facilitate the project. MCOA will invest cash and stock to complete the agreement. With the recent legalization of cannabis for recreational use on January 1, 2018 in California, MCOA expects to focus its attention on actualizing this opportunity in California. This JV project is solely for the purpose of cultivation of legal marijuana within the state of California and not beyond its borders. The Company will act solely as a landlord in this JV.

Investor Relations

Also in 2017, MCOA engaged NetworkNewsWire (“NNW”) for the Company’s corporate communication solutions. NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with MCOA, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.

About Marijuana Company of America, Inc.
MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About MoneyTrac Technology
MoneyTrac Technology, Inc. is a pioneer in offering a full-service solution for alternative banking and electronic financial solutions and provides all aspects of financial technology including E-Wallet and mobile apps services for businesses and companies in various “high-risk” industries. MoneyTrac’s technology platform allows for its clients to access their financial information from anywhere in the world, in addition to providing tracking and compliance to help them manage and control the flow of all revenue through their business.

About Global Hemp Group Inc.
Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and establish a greater collective valuation.

About Bougainville Ventures, Inc.
Bougainville Ventures Inc. is in the business of investing in high grow companies and industries that lease land, equipment and other growing infrastructure to licensed marijuana producers and luxury crop growers. Bougainville itself is not a licensed marijuana grower or retailer but instead focuses on providing capital to companies which act as landlords and equipment leasing companies to licensed marijuana producers and luxury crop growers. The Company is in the process of being listed on the CSE in Canada.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Tags: , , , , , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America’s $MCOA Overview of 2017 Highlights $AERO $CBDS $CGRW $APH.ca $GBLX

World Health Group: Pot’s #CBD Has Health Benefits #Marijuana $MCOA $N.ca $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 4:25 PM on Tuesday, December 19th, 2017
  • Compound found in the cannabis plant is not harmful, has health benefits, and does not have abuse potential, experts at the World Health Organization say.
  • WHO’s Expert Committee on Drug Dependence focused on cannabidiol, or CBD, one of the naturally occurring cannabinoids found in cannabis plants

After reviewing evidence from animal and human studies, the committee concludes that “In humans, CBD exhibits no effects indicative of any abuse or dependence potential.”

Slideshow: Medical Marijuana

1/10

What Is Medical Marijuana?

Medical marijuana is any part of the marijuana plant that you use to treat health problems. People use it to get relief from their symptoms, not to try to get high.

Most marijuana that’s sold legally as medicine has the same ingredients as the kind that people use for pleasure. But some medical marijuana is specially grown to have less of the chemicals that cause feelings of euphoria.

The experts also say that CBD might be able to treat epilepsy (where most research has focused), although results are mixed. Other conditions it might treat are Alzheimer’s disease, Parkinson’s, anxiety, depression, and other maladies. CBD may ease inflammation, provide antioxidants, and relieve pain.

Based on its research, the committee concluded that current information does not call for scheduling of the drug. In the U.S., CBD is a Schedule 1 controlled substance. These are defined as drugs with no medical use and likely to be abused.

Twenty-nine states and Washington, D.C., have legalized the use of marijuana for recreational or medicinal purposes. Other states, including Georgia, have legalized the possession of CBD to treat specific disorders.

It remains a federal crime, however, to have or sell any form of marijuana, including CBD. Despite those federal regulations, CBD is an ingredient in popular products sold over the counter as oils, extracts, supplements, and gum to treat many ailments.

CBD usually is given as a capsule or dissolved in liquid to be taken orally, under the tongue, or as a nasal spray. CBD does not produce the high that another cannabinoid — tetrahydrocannabinol (THC) — does, experts say. In fact, CBD appears to have effects opposite of THC.

The WHO announcement drew a positive response from marijuana advocates and criticism from those who don’t want it to be legal.

The experts produced the report in November, while the WHO announced its conclusions this week. In May, the committee will study cannabis and cannabis-related substances more fully.

Other major studies have shown marijuana and its products can relieve pain, nausea related to cancer treatment, and multiple sclerosis-related muscle spasms. But using cannabis has well-known short-term and long-term health effects, such as learning and coordination problems.

Because federal law makes it a crime to have marijuana and CBD, researchers must pass strict government scrutiny just to study its usefulness.

DEA View of CBD

The conclusion of the WHO flies in the face of the view of the U.S. Drug Enforcement Administration (DEA). It says that CBD must be treated the same as THC and other cannabinoids from a cannabis plant, and it should remain a Schedule I drug.

NORML Response

Marijuana advocates applauded the WHO’s conclusion. “It was terrific to see WHO acknowledge what other scientific research has already stated,” says Justin Strekal, political director of the National Organization for the Reform of Marijuana Laws (NORML).

In an email statement, he adds: “While we are pleased to see the WHO finally acknowledge that absurdity of international restrictions, the continued domestic classification and criminalization of cannabidiol as a Schedule I controlled substance is out of step with both available science and common sense. It is yet another example of the U.S. government placing ideology over evidence when it comes to issues related to the cannabis plant.”

CALM Response

Scott Chipman, Southern California chairman of Citizens Against Legalizing Marijuana (CALM), took issue with the report.

“We need to maintain a strict scientific perspective and protocols when it comes to new drugs,” he says. “We need double-blind studies related to marijuana and all components, research on the harms versus the benefits, identification of the side effects and specific ailments identified through these studies — even for CBD,” he says.

He says some ongoing drug studies of CBD do show promise in treating seizure disorders, but he also sees potential problems with the drugs, along with concerns about contamination and other potential harms with over-the-counter products.

Source: https://www.webmd.com/a-to-z-guides/news/20171215/world-health-group-pots-cbd-has-health-benefits

Tags: , , ,
Posted in All Recent Posts, Marijuana Company of America, Medical Marijuana Stocks, Namaste Technologies Inc., Tetra Bio-Pharma Inc. | Comments Off on World Health Group: Pot’s #CBD Has Health Benefits #Marijuana $MCOA $N.ca $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

« Older Entries
Newer Entries »